Annual sales of effexor.

No definition available.

Name:	teva_AnnualSales
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Classes of Direct Purchaser Plaintiffs Filed Claims

+ References

No definition available.

+ Details

Name:	teva_ClassesOfDirectPurchaserPlaintiffsFiledClaims
Namespace Prefix:	teva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

European Commission Surety Underwritten Guarantees

+ References

No definition available.

+ Details

Name:	teva_EuropeanCommissionSuretyUnderwrittenGuarantees
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Litigation fine amount of copaxone.

+ References

No definition available.

+ Details

Name:	teva_LitigationFineAmount
Namespace Prefix:	teva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Annual sales of the time of new launch of Atripla.

+ References

No definition available.

+ Details

Name:	teva_NumberOfCompetitionAndMarketsAuthorityInvestigations
Namespace Prefix:	teva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of Competition and Markets Authority Investigations Agreed to Indemnity

+ References

No definition available.

+ Details

Name:	teva_NumberOfCompetitionAndMarketsAuthorityInvestigationsAgreedToIndemnity
Namespace Prefix:	teva_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Number of claims dismissed.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-9

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-4

+ Details

Name:	us-gaap_LossContingencyClaimsDismissedNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of claims settled.

+ References

+ Details

Name:	us-gaap_LossContingencyClaimsSettledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of loss (reversal of loss) recognized for loss contingency liability. Includes, but is not limited to, effect of revision in previously reported estimate.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 450
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483076/450-20-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (j)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-22

+ Details

Name:	us-gaap_LossContingencyLossInPeriod
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The total number of new claims filed pertaining to a loss contingency during the period.

+ References

+ Details

Name:	us-gaap_LossContingencyNewClaimsFiledNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of pending claims pertaining to a loss contingency.

+ References

+ Details

Name:	us-gaap_LossContingencyPendingClaimsNumber
Namespace Prefix:	us-gaap_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_OtherCommitmentsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	srt_ProductOrServiceAxis=teva_ValsartanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_ParagardMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_VenlafaxineMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_EffexorMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_LamictalMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_NiaspanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_TruvadaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_AtriplaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_COPAXONEMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_RevlimidMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_NuvigilMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=teva_XifaxanMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and contingencies - Patent Litigation, Product Liability Litigation and Competition Matters (Detail) € in Millions, $ in Millions				1 Months Ended								12 Months Ended
	Aug. 31, 2026 case	Aug. 19, 2025 claim	Dec. 16, 2024 claim	Nov. 30, 2022 claim	Sep. 30, 2018 USD ($)	Jul. 31, 2014 USD ($)	Sep. 30, 2013 USD ($)	Apr. 30, 2013 USD ($)	Feb. 29, 2012 USD ($) claim	Dec. 31, 2011 USD ($) claim	Jul. 31, 2008 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Dec. 31, 2012 USD ($)	Sep. 30, 2026 case	Aug. 06, 2026 case	Jan. 31, 2025 EUR (€)	Oct. 31, 2024 EUR (€)	Oct. 06, 2023 claim	Jul. 15, 2021 investigation	Jan. 09, 2017 investigation
Other Commitments [Line Items]
Loss contingency accrual, provision						$ 235.5
European Commission Surety underwritten guarantees \| €																			€ 462.6
Number of Competition and Markets Authority investigations \| investigation																						3
Number of Competition and Markets Authority investigations agreed to indemnity \| investigation																							2
Valsartan
Other Commitments [Line Items]
Pending claims \| case																	235
Paragard
Other Commitments [Line Items]
Pending claims \| case																		4
Claims dismissed \| case	1
Venlafaxine
Other Commitments [Line Items]
New claims filed \| claim										3
Claims settled \| claim		1
Effexor
Other Commitments [Line Items]
Annual sales										$ 2,600.0
Lamictal
Other Commitments [Line Items]
Classes of Direct Purchaser Plaintiffs Filed Claims \| claim									2
Annual sales									$ 950.0		$ 2,300.0
Niaspan
Other Commitments [Line Items]
Annual sales							$ 1,100.0	$ 416.0
Truvada
Other Commitments [Line Items]
Annual sales												$ 2,100.0			$ 2,400.0
Atripla
Other Commitments [Line Items]
Annual sales												$ 444.0		$ 2,900.0
COPAXONE
Other Commitments [Line Items]
Litigation fine amount \| €																				€ 462.6
Revlimid
Other Commitments [Line Items]
Pending claims \| claim																					2
New claims filed \| claim			5	2
Annual sales													$ 3,500.0
Nuvigil
Other Commitments [Line Items]
Annual sales																$ 300.0
Xifaxan
Other Commitments [Line Items]
Annual sales					$ 1,500.0